Global law firm White & Case has advised Recordati S.p.A., an international pharmaceutical group listed on the Italian Stock Exchange, on a financing for the acquisition from Sanofi of the global rights to Enjaymo®.
Biologic Enjaymo® (the brand name for monoclonal antibody sutimlimab) is the only approved targeted therapy for the treatment of cold agglutinin disease, a rare B-cell lymphoproliferative disorder. Enjaymo® generated approximately €100 million in revenue in the twelve months ending August 2024.
The White & Case team in Milan that advised on the transaction included partner Iacopo Canino, local partner Bianca Caruso and associate Amedeo Bardelli.
Press contact
For more information please speak to your local media contact.
Contacts
Associate|Milan